Cancer immunotherapy: accomplishments to date and future promise.

Cancer remains a devastating disease as existing therapies are too often ineffective and toxicities remain unacceptably high. Immunotherapies for cancer offer the promise of the specificity and memory of the immune system against malignant cells to achieve durable cure with minimal toxicity. Beginning with the success of bone marrow transplantation for blood-borne cancers, and the more recent development of monoclonal antibody therapeutics for a variety of tumors, immunotherapies are already among the most successful class of treatments for cancer. Greater understanding of immunoregulatory mechanisms and improved techniques for immune cell manipulation and engineering have led to new immunomodulatory approaches and cell-based therapies for cancer that have generated great excitement within the biomedical community. As these technologies continue to improve, and as new approaches for harnessing the power and specificity of the immune system are developed, immunotherapies will play an increasingly important role in the treatment of cancer. Here, we review the history of immunotherapies for cancer and discuss existing and emerging immunotherapy technologies that hope to translate the promise of immunotherapy into clinical reality.

[1]  G. Bepler,et al.  Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[2]  G. Coukos,et al.  In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). , 2011, Cancer research.

[3]  L. Old Immunotherapy for cancer. , 1996, Scientific American.

[4]  M. Martelli,et al.  Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. , 1998, The New England journal of medicine.

[5]  D. Gabrilovich,et al.  Myeloid-derived suppressor cells. , 2007, Advances in experimental medicine and biology.

[6]  R. Storb,et al.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.

[7]  R. Prehn,et al.  Immunity to methylcholanthrene-induced sarcomas. , 1957, Journal of the National Cancer Institute.

[8]  S. Sleijfer,et al.  Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Eggermont,et al.  Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Herberman,et al.  Evaluation of cell-mediated cytotoxic reactivity against tumor associated antigens with 125I-iododeoxyuridine labeled target cells. , 1973, Journal of immunology.

[11]  David L. Porter,et al.  T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.

[12]  R. Kiessling,et al.  „Natural”︁ killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype , 1975, European journal of immunology.

[13]  W. Zou Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.

[14]  O. Finn,et al.  Tumor antigens and tumor antigen discovery. , 2005, Cancer treatment and research.

[15]  Gang Wang,et al.  A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer , 2006, Clinical Cancer Research.

[16]  H. Kolb Graft-versus-leukemia effects of transplantation and donor lymphocytes. , 2008, Blood.

[17]  D. Lubaroff Prostate cancer vaccines in clinical trials , 2012, Expert review of vaccines.

[18]  N. Senzer,et al.  Oncolytic viruses for induction of anti-tumor immunity. , 2012, Current pharmaceutical biotechnology.

[19]  W. Coley The Classic: The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas , 1991 .

[20]  Adrian P Gee,et al.  Inducible apoptosis as a safety switch for adoptive cell therapy. , 2011, The New England journal of medicine.

[21]  Zlatko Trajanoski,et al.  Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Neri,et al.  Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends , 2011, Clinical Cancer Research.

[23]  M. Burnet Cancer—A Biological Approach , 1957, British medical journal.

[24]  J. Yewdell,et al.  Identification of human cancers deficient in antigen processing , 1993, The Journal of experimental medicine.

[25]  G. Rabinovich,et al.  Immunosuppressive strategies that are mediated by tumor cells. , 2007, Annual review of immunology.

[26]  T. Treasure,et al.  Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Baccarani,et al.  Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. , 2011, Blood.

[28]  S. Loi,et al.  Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experience. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[29]  S. Steinberg,et al.  Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.

[30]  Drew A. Torigian,et al.  CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011, Science.

[31]  F. Hagemeister,et al.  Denileukin diftitox: a novel immunotoxin , 2009, Expert opinion on biological therapy.

[32]  F. Marincola,et al.  gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. , 2011, The New England journal of medicine.

[33]  F. Shanahan,et al.  Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-β expression , 2003, British Journal of Cancer.

[34]  Beverly A. Teicher,et al.  Transforming Growth Factor-β and the Immune Response to Malignant Disease , 2007, Clinical Cancer Research.

[35]  A. Ashkar,et al.  Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity , 2011, Cancer Gene Therapy.

[36]  Jinjuan Wang,et al.  Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. , 2008, Blood.

[37]  C. Le,et al.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.

[38]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[39]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[40]  M. Merino,et al.  T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[41]  F. Marincola,et al.  Prediction of response to anticancer immunotherapy using gene signatures. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  H. Stam,et al.  The spontaneous regression of cancer. A review of cases from 1900 to 1987. , 1990, Acta oncologica.

[43]  Nina Bhardwaj,et al.  Consequences of cell death: exposure to necrotic tumor cells , 2000 .

[44]  Y. Nishikawa,et al.  Oncolytic herpes virus induces effective anti-cancer immunity against murine colon cancer. , 2011, Hepato-gastroenterology.

[45]  Z. Trajanoski,et al.  Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.

[46]  S. Latour,et al.  Essential function for SAP family adaptors in the surveillance of hematopoietic cells by natural killer cells , 2009, Nature Immunology.

[47]  F. Errington,et al.  Oncolytic Viruses: Do They Have a Role in Anti-Cancer Therapy? , 2008, Clinical medicine. Oncology.

[48]  O. Finn,et al.  Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  T. Whiteside,et al.  Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. , 2007, Cancer research.

[50]  C. Klebanoff,et al.  Paths to stemness: building the ultimate antitumour T cell , 2012, Nature Reviews Cancer.

[51]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[52]  S. Rosenberg,et al.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.

[53]  H. Ljunggren,et al.  Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy , 1986, Nature.

[54]  J. Friedberg,et al.  Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. , 2009, Blood.

[55]  T. Whiteside,et al.  Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment , 2007, Cancer Immunology, Immunotherapy.

[56]  Steven A. Rosenberg,et al.  Adoptive immunotherapy for cancer: harnessing the T cell response , 2012, Nature Reviews Immunology.

[57]  S. Rosenberg,et al.  Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression , 2011, Clinical Cancer Research.

[58]  M. Dhodapkar,et al.  Antitumor Monoclonal Antibodies Enhance Cross-Presentation of Cellular Antigens and the Generation of Myeloma-specific Killer T Cells by Dendritic Cells , 2002, The Journal of experimental medicine.

[59]  S. Rosenberg,et al.  Telomere Length of Transferred Lymphocytes Correlates with In Vivo Persistence and Tumor Regression in Melanoma Patients Receiving Cell Transfer Therapy1 , 2005, The Journal of Immunology.

[60]  A. Enk,et al.  Depletion of CD4+CD25+ human regulatory T cells in vivo: Kinetics of Treg depletion and alterations in immune functions in vivo and in vitro , 2007, International journal of cancer.

[61]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[62]  A. Friedman,et al.  Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. , 2006, Cancer research.

[63]  Hans Schreiber,et al.  Specificity in cancer immunotherapy. , 2008, Seminars in immunology.

[64]  P. Murawa,et al.  The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial , 2010, International journal of cancer.

[65]  I. Weissman,et al.  Programmed cell removal: a new obstacle in the road to developing cancer , 2011, Nature Reviews Cancer.

[66]  R. Sims Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer. , 2012, Vaccine.

[67]  Louis M. Weiner,et al.  Antibody-Based Immunotherapy of Cancer , 2012, Cell.

[68]  D. Munn,et al.  Prevention of allogeneic fetal rejection by tryptophan catabolism. , 1998, Science.

[69]  Ximing J. Yang,et al.  Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. , 2005, Cancer research.

[70]  S. Geary,et al.  Prostate cancer vaccines , 2013, Oncoimmunology.

[71]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[72]  C. Vajdic,et al.  Cancer incidence and risk factors after solid organ transplantation , 2009, International journal of cancer.

[73]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[74]  G. Coukos,et al.  Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. , 2001, Cancer research.

[75]  A. Oseroff,et al.  Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  A. Chang,et al.  Adoptive Transfer of Tumor Reactive B Cells Confers Host T-Cell Immunity and Tumor Regression , 2011, Clinical Cancer Research.

[77]  Rui-Ru Ji,et al.  An immune-active tumor microenvironment favors clinical response to ipilimumab , 2012, Cancer Immunology, Immunotherapy.

[78]  T. Braun,et al.  Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  E. Jaffee,et al.  Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. , 2005, Cancer research.

[80]  T. Waldmann,et al.  Immunotherapy: past, present and future , 2003, Nature Medicine.

[81]  Ash A. Alizadeh,et al.  CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells , 2009, Cell.

[82]  J. Rommelaere,et al.  Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment , 2012, Cancer Immunology, Immunotherapy.

[83]  A. Eggermont Can immuno-oncology offer a truly pan-tumour approach to therapy? , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[84]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[85]  J. Kirkwood,et al.  Next generation of immunotherapy for melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  S. Rosenberg,et al.  T-cell therapy at the threshold , 2012, Nature Biotechnology.

[87]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[88]  A. Órfão,et al.  Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. , 2006, Journal of the National Cancer Institute.

[89]  B. Shalmon,et al.  Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients , 2010, Clinical Cancer Research.

[90]  R. Patt,et al.  Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[91]  G. Prendergast,et al.  Indoleamine 2,3-dioxygenase in immune suppression and cancer. , 2007, Current cancer drug targets.

[92]  S. Rosenberg,et al.  Prevention of Interleukin-2 Withdrawal-Induced Apoptosis in Lymphocytes Retrovirally Cotransduced With Genes Encoding an Antitumor T-cell Receptor and an Antiapoptotic Protein , 2010, Journal of immunotherapy.

[93]  A. Lawson,et al.  Activation of Resting Human Primary T Cells with Chimeric Receptors: Costimulation from CD28, Inducible Costimulator, CD134, and CD137 in Series with Signals from the TCRζ Chain , 2004, The Journal of Immunology.

[94]  V. Grdzelishvili,et al.  Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. , 2012, The Journal of general virology.

[95]  Michel Sadelain,et al.  The promise and potential pitfalls of chimeric antigen receptors. , 2009, Current Opinion in Immunology.

[96]  B. Shalmon,et al.  Establishment and Large-scale Expansion of Minimally cultured “Young” Tumor Infiltrating Lymphocytes for Adoptive Transfer Therapy , 2011, Journal of immunotherapy.

[97]  L. Zitvogel,et al.  Trial Watch , 2012, Oncoimmunology.

[98]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[99]  R. Kiessling NATURAL KILLER CELLS IN THE MOUSE , 1976 .

[100]  Israel Lowy,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  William B. Colev I. The Treatment of Malignant Tumors by Repeated Inoculations of Erysipelas , 1893 .

[102]  Henrik Schmidt,et al.  A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma , 2011, Journal of Translational Medicine.

[103]  M. Slovak,et al.  Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[104]  M. Brenner,et al.  Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells , 2006, Leukemia.

[105]  J. Wolchok,et al.  Antibody therapy of cancer , 2012, Nature Reviews Cancer.

[106]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[107]  S. Rosenberg,et al.  Transduction of an IL-2 Gene into Human Melanoma-Reactive Lymphocytes Results in Their Continued Growth in the Absence of Exogenous IL-2 and Maintenance of Specific Antitumor Activity , 2001, The Journal of Immunology.

[108]  Bart Spiessens,et al.  Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  Eric Vivier,et al.  Targeting natural killer cells and natural killer T cells in cancer , 2012, Nature Reviews Immunology.

[110]  M. Peshwa,et al.  Dendritic cell-based treatment of cancer: closing in on a cellular therapy. , 2001, Cancer journal.

[111]  W. Burns,et al.  Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. , 2011, Blood.

[112]  Z. Eshhar,et al.  Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[113]  S. Rosenberg,et al.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. , 1994, JAMA.

[114]  S. Rosenberg,et al.  Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. , 1999, Journal of immunology.

[115]  M. Essand,et al.  Genetically engineered T cells for the treatment of cancer , 2013, Journal of internal medicine.

[116]  R. Figlin,et al.  A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[117]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[118]  R. Herberman,et al.  Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells , 1975, International journal of cancer.